Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 20/20 | 0.69 |
| ▸ | MTNR1B | P49286 | 18/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8128191 | 0.82 | MTNR1A (1.00) | MTNR1AMTNR1BKDM4EALDH1A1CYP1A2 | |
| SCHEMBL6251228 | 0.79 | MTNR1A (0.69) | MTNR1AMTNR1B | |
| SCHEMBL8134740 | 0.76 | MTNR1A (0.63) | MTNR1AMTNR1BKDM4EALDH1A1CYP1A2 | |
| SCHEMBL8124279 | 0.74 | MTNR1A (0.75) | MTNR1AMTNR1BKDM4EALDH1A1CYP1A2 | |
| SCHEMBL8136831 | 0.71 | MTNR1A (0.56) | MTNR1AMTNR1B | |
| SCHEMBL8127354 | 0.71 | MTNR1A (0.80) | MTNR1AMTNR1BKDM4EALDH1A1CYP3A4 | |
| SCHEMBL8131821 | 0.70 | MTNR1A (1.00) | MTNR1AMTNR1BKDM4EALDH1A1HPGD | |
| SCHEMBL8131312 | 0.69 | MTNR1A (1.00) | MTNR1AMTNR1BKDM4EALDH1A1HPGD | |
| SCHEMBL3508630 | 0.69 | MTNR1A (1.00) | MTNR1AMTNR1BKDM4EALDH1A1CYP1A2 | |
| SCHEMBL8130418 | 0.69 | MTNR1A (0.61) | MTNR1AMTNR1BKDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005063240-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF HYPERTENSION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-07-14 | — | — | WO | claimed |
| US-20050137247-A1 | Methods and compositions for treatment of hypertension | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-06-23 | — | — | US | claimed |
| WO-2024155777-A2 | COMPOSITIONS AND TECHNIQUES FOR TREATMENT OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AND ENDOMETRIOSIS | DARE BIOSCIENCE, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-9468670-B2 | Melatonin-based treatment and diagnosis of bile duct disease | TEXAS A&M UNIVERSITY SYSTEM (US) | 2016-10-18 | — | — | US | disclosed |
| US-20140079680-A1 | MELATONIN-BASED TREATMENT AND DIAGNOSIS OF BILE DUCT DISEASE | SCOTT & WHITE HEALTHCARE (US) | 2014-03-20 | — | — | US | disclosed |
| WO-2012135848-A2 | MELATONIN-BASED TREATMENT AND DIAGNOSIS OF BILE DUCT DISEASE | SCOTT & WHITE HEALTHCARE (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2005063240-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF HYPERTENSION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050137247-A1 | Methods and compositions for treatment of hypertension | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137247-A1 | Methods and compositions for treatment of hypertension | REN, MTNR1A, MTNR1B | MTNR1A 2/4885MTNR1B 3/4885KDM4E 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.